Cargando…

Anti-C1q Antibodies as a Follow-Up Marker in SLE Patients

In cross-sectional studies autoantibodies against complement C1q (anti-C1q) were found to be highly associated with active lupus nephritis. The aim of this retrospective study was to determine the value of anti-C1q as follow-up marker of disease activity and renal involvement in patients with system...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bock, Merete, Heijnen, Ingmar, Trendelenburg, Marten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400137/ https://www.ncbi.nlm.nih.gov/pubmed/25881125 http://dx.doi.org/10.1371/journal.pone.0123572

Ejemplares similares

Autoantibodies against complement component C1q in systemic lupus erythematosus
por: Trendelenburg, Marten
Publicado: (2021)

Anti‐C1q autoantibodies from systemic lupus erythematosus patients enhance CD40–CD154‐mediated inflammation in peripheral blood mononuclear cells in vitro
por: Rabatscher, Pascal Alexander, et al.
Publicado: (2022)

C1q as a target molecule to treat human disease: What do mouse studies teach us?
por: Schulz, Kristina, et al.
Publicado: (2022)

Worse cardiovascular and renal outcome in male SLE patients
por: Mihailovic, Jelena, et al.
Publicado: (2023)

Anti-C1q Antibodies as Occurring in Systemic Lupus Erythematosus Could Be Induced by an Epstein-Barr Virus-Derived Antigenic Site
por: Csorba, Kinga, et al.
Publicado: (2019)

Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up
por: Pesickova, Satu Sinikka, et al.
Publicado: (2015)

Complement C1q Enhances Primary Hemostasis
por: Donat, Claudia, et al.
Publicado: (2020)

Binding of von Willebrand Factor to Complement C1q Decreases the Phagocytosis of Cholesterol Crystals and Subsequent IL-1 Secretion in Macrophages
por: Donat, Claudia, et al.
Publicado: (2019)

Epitope-Specific Anti-C1q Autoantibodies in Systemic Lupus Erythematosus
por: Kleer, Jessica S., et al.
Publicado: (2022)

A Trial of Complement Inhibition in a Patient with Cryoglobulin-Induced Glomerulonephritis
por: Hirt-Minkowski, Patricia, et al.
Publicado: (2012)

Role of serum anti-C1q antibodies as a biomarker for nephritis activity in pediatric and adolescent Egyptian female patients with SLE
por: Abdel Kader, Mohamed Salah Eldin Mohamed, et al.
Publicado: (2012)

Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study
por: Charitos, Panteleimon, et al.
Publicado: (2021)

Pathogenic and Epiphenomenal Anti-DNA Antibodies in SLE
por: Pavlovic, Mirjana, et al.
Publicado: (2010)

The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies
por: Wang, Yaqi, et al.
Publicado: (2021)

Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis
por: Friebus-Kardash, Justa, et al.
Publicado: (2019)

Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study
por: Osthoff, Michael, et al.
Publicado: (2019)

Monocyte Expressed Macromolecular C1 and C1q Receptors as Molecular Sensors of Danger: Implications in SLE
por: Ghebrehiwet, Berhane, et al.
Publicado: (2014)

Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease
por: Hu, Shui-yi, et al.
Publicado: (2013)

Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE
por: Reynolds, John A, et al.
Publicado: (2023)

Elevated anti-serum amyloid P component (SAP) antibodies in SLE patients
por: Zandman-Goddard, G, et al.
Publicado: (2003)

Do anti-DFS70 antibodies temper disease activity and progression in SLE?
por: Choi, May Y, et al.
Publicado: (2021)

The Lectin Pathway of Complement in Myocardial Ischemia/Reperfusion Injury—Review of Its Significance and the Potential Impact of Therapeutic Interference by C1 Esterase Inhibitor
por: Panagiotou, Anneza, et al.
Publicado: (2018)

Factors Associated With Use of Telemedicine for Follow-Up of SLE in the COVID-19 Outbreak
por: So, Ho, et al.
Publicado: (2021)

A High Prevalence of Anti-EBNA1 Heteroantibodies in Systemic Lupus Erythematosus (SLE) Supports Anti-EBNA1 as an Origin for SLE Autoantibodies
por: Laurynenka, Viktoryia, et al.
Publicado: (2022)

Case Report—Secondary Antibody Deficiency Due to Endogenous Hypercortisolism
por: Sarcevic, Jelena, et al.
Publicado: (2020)

Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE) †
por: Ponticelli, Claudio, et al.
Publicado: (2010)

Blood group antigens SLeX, SLeA, and LeY as prognostic markers in endometrial cancer
por: Kolben, Thomas, et al.
Publicado: (2022)

Anti‐dsDNA, anti‐nucleosome, anti‐C1q, and anti‐histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity
por: Shang, Xiaoying, et al.
Publicado: (2021)

Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage
por: McDonnell, Thomas, et al.
Publicado: (2022)

Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial
por: Urwyler, Pascal, et al.
Publicado: (2023)

Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System
por: Urwyler, Pascal, et al.
Publicado: (2020)

Inflammation associated anemia and ferritin as disease markers in SLE
por: Vanarsa, Kamala, et al.
Publicado: (2012)

1. SLE and Pregnancy
por: Khan, Afsha, et al.
Publicado: (2017)

Loss of antiphospholipid antibody positivity post-thrombosis in SLE
por: Khawaja, Muznay, et al.
Publicado: (2020)

Targeting thromboinflammation in COVID-19 – A narrative review of the potential of C1 inhibitor to prevent disease progression
por: Urwyler, Pascal, et al.
Publicado: (2022)

Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy
por: Nunez, Daniel, et al.
Publicado: (2023)

Clinical utility of anti-C1q antibody in primary and secondary vasculitic conditions
por: Jayakanthan, Kabeerdoss, et al.
Publicado: (2017)

B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels
por: Lazarus, Mark N., et al.
Publicado: (2012)

Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
por: Urwyler, Pascal, et al.
Publicado: (2021)

Central retinal vein occlusion in a pediatric patient with SLE and antiphospholipid antibodies without anti-cardiolipin or anti-β2 glycoprotein I antibodies
por: Korematsu, Seigo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vnekf2a20l2g5vq8qtst1u3qjv